Axsome therapeutics announces fda acceptance of nda resubmission for axs-07 for the acute treatment of migraine

New york, sept. 04, 2024 (globe newswire) -- axsome therapeutics, inc. (nasdaq: axsm), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (cns) disorders, today announced that the u.s. food and drug administration (fda) has acknowledged the resubmission of the company's new drug application (nda) for axs-07 for the acute treatment of migraine.
AXS Ratings Summary
AXS Quant Ranking